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Abstract: Acne	is	a	chronic,	immune-mediated,	inflammatory	disease	with	high	prevalence	among	adolescents.	By	compro-
mising	face,	thorax	and	back,	with	the	risk	of	permanent	scars,	it	has	a	negative	impact	on	the	quality	of	life.	Effective,	safe	
and	early	treatment	is	the	key	to	remission,	while	decreasing	the	risk	of	physical	and/or	emotional	sequelae.	The	Iberian-
-Latin	American	Group	of	Acne	Studies	joined	professionals	with	expertise	and	developed	a	practical	therapeutic	algorithm,	
adapted	to	the	reality	of	Latin	American	countries,	Spain	and	Portugal.	This	article	intends	to	disseminate	it	with	an	updated	
review	on	a	rational,	safe	and	effective	acne	treatment.
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INTRODUCTION
Acne	 is	one	of	 the	most	 common	dermatological	diseases	
seen	 by	 dermatologists	 in	 Latin	America,	 Spain	 and	 Portugal,	 as	
well	as	in	the	rest	of	the	world.	It	is	a	chronic	inflammatory	process	
that	 needs	 to	 be	 treated	 early	 and	 effectively	 to	decrease	 the	 risk	
of	physical	and	emotional	sequelae.	 In	this	article,	we	present	 the	
result of the consensus among a group of dermatologists from Latin 
America,	Spain	and	Portugal,	based	on	the	scientific	evidence	avail-
able in the literature and the experience of the members.
METHODS
A	group	of	33	dermatologists,	members	of	the	Iberian-Latin	
American	College	of	Dermatology	-	CILAD,	and	well-known	acne	
specialists,	created	the	Iberian-Latin	American	Group	for	the	Study	
of	Acne	-	GILEA.	All	the	available	scientific	evidence	was	carefully	
chosen	and	several	questions	were	developed	 in	different	 face-to-
face	meetings	to	initially	determine	the	classification	and	gradation	
of	the	disease	and	subsequently	the	guidelines	for	the	treatment	of	
acne	or	therapeutic	algorithm.	Through	these	meetings	and	others,	
conducted	 in	 electronic	 format	 (e.g.	 Skype,	 e-mail)	 between	 2012	
and	2016,	questions	based	on	scientific	evidence	and	participants’	
experiences	were	circulated	until	a	consensus	was	reached,	which	
resulted	 in	 the	 therapeutic	 algorithm	 in	 Portuguese,	 Spanish	 and	
English	 adapted	 to	 the	 Iberian-Latin	American	 conditions,	 that	 is	
presented	in	this	paper	(Figures	1,	2	and	3).	
TOPICAL	TREATMENT
Topical treatment can be indicated as monotherapy or in com-
bination	with	systemic	antibiotics	or	hormonal	treatment,	depending	
on	 the	 type	of	acne.	The	majority	of	patients	with	comedonal	acne	
respond to topical treatment associated or not with dermocosmetics.1
Received on 05.02.2017.
Approved	by	the	Advisory	Board	and	accepted	for	publication	on	25.05.2017.
*		 Study	conducted	at	the	Colégio	Ibero-Latino	Americano	de	Dermatologia	-	Buenos	Aires,	Argentina.
 Financial support: none.
	 Conflict	of	interest:	none.
1.		 Department	of	Dermatology	-	Escola	Paulista	de	Medicina	-	Universidade	Federal	de	São	Paulo	(EPM-Unifesp)	–	São	Paulo	(SP),	Brazil.
2	 Department	of	Dermatology,	“Herbert	Wertheim”	College	of	Medicine-	Florida	International	University	–	Florida,	USA.
3	 Private	Clinic	–	Mexico	City,	Mexico.
4	 Department	of	Dermatology,	School	of	Medicine.	Universidad	de	Buenos	Aires,	Argentina.
		 ©2017	by	Anais	Brasileiros	de	Dermatologia
Retinoids
Considered	 the	first-line	 therapy	 for	 comedonal	 acne,	 ret-
inoids	 normalize	 infundibular	 keratinization,	 inhibit	 comedogen-
esis,	 have	 an	 anti-inflammatory	 action	 and	 also	 increase	 the	pen-
etration of other medications. They act by binding to cytoplasmic 
(CRAB)	 and	 nuclear	 receptors	 (retinoic	 acid	 receptors	 or	 RARs	
and	X	or	RXRs)	and	regulate	the	expression	of	genes	related	to	cell	
differentiation,	lipid	metabolism,	apoptosis	and	cell	cycle.	The	an-
ti-inflammatory	activity	of	retinoids	is	due	to	the	modulation	of	the	
Toll-like	 receptors	 (TLR),	 the	 innate	 immunity,	 and	 the	 surface	of	
sebocytes	 that	 bind	 to	molecular	 patterns	 of	 the	microorganisms,	
in	this	case,	cell	wall	peptidoglycans	of	the	Propionibacterium acnes 
(P. acnes),	activating	signaling	pathways,	such	as	NF-κB,	with	pro-
duction	of	proinflammatory	cytokines.2 Two groups are available: 
first	 generation,	 tretinoin	or	 all-trans	 retinoic	 acid	 (concentrations	
of	0.025%,	0.05%	and	0.1%)	and	isotretinoin	or	13-cis-retinoic	acid	
(sparingly	used)	and	synthetic	retinoids,	adapalene	and	tazarotene,	
the latter not available in many countries. Tretinoin and adapalene 
are	classified	as	Class	C	and	Tazarotene	as	X	by	the	Food	and	Drug	
Administration	 (FDA)	 -	 the	 United	 States	 regulatory	 agency.	 Re-
cently	the	FDA	removed	the	prescription	need	for	adapalene	0.1%,	
based on a meta-analysis that showed no increase in the incidence of 
congenital	malformations,	abortion,	low	birth	weight	or	prematuri-
ty	in	women	who	used	adapalene	during	pregnancy.	For	tretinoin,	
the recommendation not to use during gestation was maintained.3 
Irritant	contact	dermatitis	 (erythema,	pruritus,	desquamation),	 in-
creased	 risk	 of	 photosensitivity	 and	 postinflammatory	 pigmenta-
tion	are	attenuated	by	the	use	of	moisturizers	and	photoprotectors.	
They	may	be	used	alone	or	in	combination	with	benzoyl	peroxide	
(PB)	and	topical	antibiotics.1,4
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Benzoyl peroxide
 PB is an antimicrobial agent with activity against P. acnes by 
the	release	of	reactive	oxygen	species	(ROS),	and	mild	comedolytic	
effect.	There	is	no	description	of	PB-resistant	strains;	moreover,	its	
use in combination with topical or systemic antibiotics prevents and 
treats	 bacterial	 resistance.	Available	 concentrations,	 ranging	 from	
2.5%	to	10%,	appear	to	have	the	same	effectiveness;	however,	irri-
tant	contact	dermatitis	is	more	frequent	with	higher	concentrations.1
Topical antibiotics
Topical antibiotics accumulate in the follicle and present an-
ti-inflammatory	and	antimicrobial	effect.	Its	use	as	monotherapy	is	
not	recommended,	but	combined	with	PB,	it	shows	increased	effica-
cy and decreased bacterial resistance.1
Fixed combinations
Fixed combinations have advantages over monotherapy be-
cause they act on several etiopathogenic factors. They have antimi-
crobial,	anti-inflammatory	and	comedolytic	activity	while	 increas-
ing	PB	penetration.	They	are	the	first	choice	for	mild	to	moderate	
papular-pustular acne. The available options are: PB with clinda-
mycin	 or	 erythromycin,	 tretinoin	 with	 clindamycin	 and	 PB	 with	
adapalene. There are two concentrations of adapalene combined 
with PB available in some countries: 0.1% for mild to moderate pus-
tular acne and 0.3% approved in the United States and indicated for 
moderate to severe forms. Use of a single product increases adher-
ence ensuring better results.5,6
Azelaic Acid (AA)
Azelaic	acid	is	a	saturated	dicarboxylic	acid	that	normalizes	
follicular	hyperkeratinization	by	a	cytostatic	effect	on	keratinocytes.	
It decreases proliferation of P. acnes by	inhibiting	protein	synthesis,	
and	reduces	 inflammation	by	activating	nuclear	PPARγ	 receptors,	
inhibiting	activation	of	NF-kB	pathway	and	blocking	the	release	of	
free	radicals.	It	also	has	a	bleaching	action.	AA	is	indicated	for	mild	
to	 moderate	 papular-pustular	 acne,	 particularly	 in	 patients	 with	
sensitive	and	darker	skin,	as	well	as	in	adult	acne	in	women.	AA	is	
Category B for use in pregnancy.1,7
SYSTEMIC TREATMENT
Oral Antibiotics
The	use	of	oral	antibiotics	 (OABs)	has	been	a	mainstay	of	
acne treatment for years.1 Their indication is papular-pustular and 
mild nodular-cystic acne. They are effective due to their antibacteri-
al,	immunosuppressive,	but	fundamentally	by	their	anti-inflamma-
tory	actions.	OABs	should	be	used	from	6	to	12	weeks.	Their	effect	
depends	 on	 gastrointestinal	 permeability,	 absorption,	 distribution	
and	penetration	into	the	skin.	The	more	soluble	and	permeable	ones	
are	better	absorbed	and	distributed,	while	the	lipophilic	ones	pene-
trate better in the pilosebaceous follicle. P. acnes is the main bacteria 
involved in the etiopathogenesis of acne. It produces lipases that 
hydrolyze	 triglycerides,	 releasing	pro-inflammatory	 fatty	acids.	P. 
acnes is	recognized	by	TLR-2	and	4,	activating	the	NF-κB	pathways,	
with	production	of	IL-6	and	IL-8	by	follicular	keratinocytes	and	IL-8	
and	 IL-12	 by	macrophages	 and	AP-1,	 with	 production	 of	 matrix	
metalloproteinases	 (MMP)	 that	 degrade	 the	 dermal	 extracellular	
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matrix	causing	scars.	Doxycycline	100	mg/day,	lymecycline	300mg/
day,	minocycline,	 100mg/day	and	 tetracycline	500mg	 twice	daily,	
are	the	most	used	OABs.	Erythromycin	1,000mg	per	day	is	recom-
mended for pregnant women and infants. Dapsone is indicated for 
patients	with	nodular-cystic	acne	at	doses	of	50	to	100mg/day.	Ad-
verse	events	of	OAB	are	gastrointestinal	(epigastralgia,	nausea	and	
vomiting);	photosensitivity	and	phototoxic	reactions	(doxycycline);	
hypersensitivity	reactions,	pigmentation	and	autoimmune	phenom-
ena	(minocycline).	Misuse	of	OABs	may	induce	bacterial	resistance	
due	to	several	factors:	monotherapy,	prolonged	use,	indiscriminate	
use	without	strict	adherence,	dose	below	recommended,	not	associ-
ation with the use of topical PB and/or retinoid and improper ro-
tational	use.	Consequences	are	not	limited	to	P. acnes,	but	to	other	
bacteria,	particularly	Staphylococcus aureus in upper respiratory tract 
infections.	It	occurs	more	frequently	with	erythromycin	(50%)	than	
with	tetracycline	derivatives	(20%).1,8 
Isotretinoin
Isotretinoin is effective and safe in the treatment of severe 
acne,	with	prolonged	remission	or	cure.1 It is a sebum-suppressive 
agent,	reducing	the	sebum	production,	the	comedogenesis	and	the	
size	of	the	sebaceous	gland.	Inhibits	terminal	sebocyte	differentia-
tion	and	alters	follicular	microenvironment,	decreasing	colonization	
by P. acnes	and	reducing	inflammation	by	modulating	TLR-2	and	4.9 
The bioavailability of the medication is increased by 25% with fat 
food	reaching	a	plasma	peak	in	2	to	4	hours.	It	has	low	affinity	for	
RARs.	It	is	a	prodrug	with	metabolite-dependent	effects	and	metab-
olized	in	the	liver	by	the	P-450	system.	Its	approved	indication	is	for	
severe nodular-cystic acne and papular-pustular acne that does not 
improve	with	conventional	treatment	or	that	present	response,	but	
with	rapid	relapse,	tendency	to	leave	scars	and	negative	psychoso-
cial	impact.	A	daily	dose	of	0.5	to	1.0mg/kg	and	a	total	dose	of	120	
to	150mg/kg	is	recommended.	In	severe	acne,	prolonged	treatment,	
higher dose of the medication or several cycles may be necessary. 
It	should	not	be	administered	with	other	retinoids,	vitamin	A,	tet-
racycline	or	derivative	antibiotics,	methotrexate,	cyclosporine	and	
imidazole	antifungals.	Common,	controllable	and	dose-dependent	
adverse	 events	 are:	 cheilitis,	 xerosis	 cutis,	 facial	 dermatitis,	 nasal	
dryness,	epistaxis,	dry	eyes,	blepharoconjunctivitis	and	contact	lens	
intolerance. Prevention and early treatment of these adverse events 
is	important	and	should	be	done	with	lip	and	nasal	balms,	lubricant	
eye	products,	skin	moisturizers	and	sunscreens.	In	patients	with	se-
vere	acne,	exacerbation,	with	new	inflammatory	lesions,	may	occur	
three	to	four	weeks	after	starting	treatment,	with	a	risk	of	scarring.	
To reduce this exacerbation the treatment should start with a daily 
low	dose,	combined	with	oral	corticosteroids	and	antibiotics	(except	
tetracyclines),	until	the	lesions	improve,	when	they	are	withdrawn	
and the dose of isotretinoin is increased. Other unpredictable events 
that are depending on dose and individual susceptibility are: eleva-
tion	of	liver	enzymes	and	triglycerides,	increase	of	serum	cholesterol	
LDL	fraction,	and	decreased	HDL	fraction	as	well	as	hematological	
changes. Laboratory monitoring is mandatory at baseline and after 
1	to	2	months.	If	tests	are	abnormal,	they	should	be	repeated	every	
month.10 Teratogenicity is the most serious and irreversible event. 
Pregnancy test is mandatory in women and must be performed ev-
ery month before the next dose of the medication. The contraceptive 
An Bras Dermatol. 2017;92(5):689-93.
692	 Bagatin	E,	Florez-White	M,	Arias-Gomez	MI,	Kaminsky	A
period,	with	two	contraceptive	methods,	should	be	one	month	be-
fore	the	beginning	of	the	treatment,	during	and	one	month	after	the	
cessation	 of	 treatment	without	 risk	 for	 future	pregnancies.1 Some 
other	adverse	events,	with	very	low	or	absent	risk	are:	bone	alter-
ations	 (premature	 closure	 of	 the	 epiphysis,	 higher	 risk	 of	 keloids	
and	 hypertrophic	 scars,	 depression,	 suicidal	 ideation	 and	 suicide	
attempt	-	on	the	contrary,	this	medication	improves	quality	of	life	-,	
and	inflammatory	bowel	disease	-	demonstrated	with	tetracyclines	
and	not	confirmed	in	population-based,	case-control	studies).11-13 the 
recurrence	of	acne	may	occur	within	the	first	year	after	treatment.	
Also,	29%	of	patients	require	more	than	one	cycle,	25%	two	cycles	
and 3% three cycles.1
Hormonal agents
For	 women,	 with	 or	 without	 hyperandrogenemia,	 hor-
monal	blockade	 is	useful	because	acne	 is	an	androgen-dependent	
disease.	This	is	a	safe	and	effective	alternative,	either	alone	or	asso-
ciated with topical treatments. The activity of the sebaceous gland 
- the production of sebum - depends on the activation of androgen 
receptors	 in	 the	sebocytes	by	androgens	produced	by	the	gonads,	
adrenal and sebaceous gland. Treatment reduces plasma and pe-
ripheral	concentration	of	androgens	and	production	and	qualitative	
changes	in	sebum,	reduce	colonization	of	P. acnes at pilosebaceous 
follicle.	The	most	commonly	used	drugs	that	block	receptors	and	in-
hibit	ovarian	production	are	cyproterone	acetate	and	drospirenone,	
present in oral contraceptives in combination with ethinyl estradiol. 
Spironolactone	(50	to	100mg/day)	may	be	used	to	block	androgen	
receptors.	To	inhibit	the	adrenal	production,	it	is	indicated	the	use	of	
low	doses	of	corticosteroids	(prednisone	2.5	to	5mg/day).14
Meta-analysis	comparing	the	efficacy	of	combined	oral	con-
traceptives	 (COCs)	 versus	 OABs	 concluded	 that	 both,	 compared	
with	 placebo,	 reduced	 acne	 lesions.	 OABs	 were	 superior	 after	 3	
months	of	treatment	and	COCs	were	equivalent	at	the	sixth	month,	
that	is,	COCs	may	represent	the	first-line	for	prolonged	treatments	
in	 adult	women.	 Their	 adverse	 events	 include	 nausea,	 headache,	
mastodynia,	 sporadic	 bleeding	 and	 decreased	 libido.	 Benefits	 in-
clude	protection	against	ovarian	and	endometrial	cancer,	reduction	
of	dysmenorrhea,	iron	deficiency	anemia,	and	pelvic	inflammatory	
disease. Incidence of venous thromboembolism in young women 
is	 low;	however,	there	is	an	increase	of	0.05%	to	0.1%	with	COCs.	
They	should	be	avoided	in	smokers,	family	history	or	risk	of	deep	
venous	 thrombosis	and	cardiovascular	disease.	 Insulin	 sensitizers	
(e.g.	metformin)	are	indicated	only	in	polycystic	ovary	syndrome,	
improving hirsutism and acne.15 
Corticosteroids
Corticosteroids	are	indicated	in	severe	nodular-cystic	acne,	
conglobata, fulminans,	and	severe	acne	at	the	beginning	of	the	treat-
ment	with	oral	 isotretinoin,	as	mentioned	before,	and	in	the	adult	
woman with adrenal hyperandrogenism. The most commonly used 
are	 prednisone,	 prednisolone,	 deflazacort,	 dexamethasone	 and	
methylprednisolone.
ADJUNCTIVE THERAPY
Cosmetic procedures
Manual	 comedone	 extraction,	 unclogs	 follicular	 infundib-
ulum,	 facilitates	 the	 penetration	 of	 topical	 products,	 providing	 a	
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positive	 impact	on	 the	quality	of	 life	 and	avoiding	 improper	ma-
nipulation of lesions by the patient and/or inexperienced people. 
The	electrocauterization	of	closed	macro-comedones	should	be	su-
perficial	to	decrease	the	risk	of	scars.	It	is	useful	to	avoid	the	evolu-
tion to papular-pustular lesions and manipulation. The intralesional 
corticosteroid	injection	(triamcinolone	acetonide)	is	used	in	isolated	
nodules,	accelerating	their	regression	and	relieving	pain,	as	well	as	
in	 hypertrophic	 and	 keloid	 scars,	with	 total	 or	 partial	 regression.	
Drainage	of	cysts	and	abscesses	 is	done	when	there	 is	fluctuation	
in	 lesions	and	 should	be	associated	with	oral	 antibiotics.	 Superfi-
cial	 chemical	 peels	 (20%	 to	 30%	 salicylic	 acid,	 Jessner’s	 solution,	
10%	trichloroacetic	acid	or	20%	aqueous	solution,	and	70%	glycolic	
acid	 in	 gel,	with	partially	 buffered	pH)	 are	useful	 for	 comedonal	
and	 papular-pustular	 acne	 by	 their	 keratolytic	 action.	 All	 cause	
temporary	burning,	erythema	and	desquamation	after	3	to	5	days	
to	 7	 to	 15	 days.	Cryotherapy	with	 liquid	 nitrogen	 is	 indicated	 to	
treat	inflammatory	nodules,	hypertrophic	scars	and	keloids,	but	its	
use	is	decreasing	due	to	the	risk	of	hypochromic	sequelae.	Micro-
dermabrasion	is	a	very	superficial	exfoliation	method	equivalent	to	
superficial	peeling,	simple	and	safe.16
Light or LED - light emitting diode - blue or red exhibits 
photochemical,	 immunomodulatory	and	anti-inflammatory	effects	
faster than drug treatment and can be associated in the early stag-
es improving adherence to treatment. Photo-pneumatic therapy is 
a relatively new technology in the treatment of acne and appears 
to be effective in moderate cases combining photochemical effects 
with mechanical extrusion of comedones in addition to a light pho-
tothermal	effect.	Among	the	laser	or	light	procedures,	the	most	evi-
dence	is	photodynamic	therapy,	which	uses	a	photosensitizer,	such	
as	 aminolevulinic	 acid,	 applied	 for	 1	 to	 3	 hours,	 during	which	 it	
is absorbed by the sebocytes and later activated by a laser or light 
device,	generating	ROS	that	damage	the	sebaceous	glands	and	re-
duce P. acnes.	Although	this	treatment	is	promising,	more	controlled	
studies	are	needed	to	determine	the	 ideal	photosensitizer,	 incuba-
tion	time,	and	light	source.17
Dermocosmetics
In	the	mild	and	early	forms	of	acne	(comedonal,	with	hyper-
seborrhea),	 salicylic	 acid-based	 dermocosmetics,	 lipo-hydroxy-ac-
ids,	retinol,	glycolic	acid	(in	low	concentrations)	and	nicotinamide	
may	be	sufficient	to	control	the	disease.	Moisturizers	help	to	reduce	
adverse events of topical products and dryness due to oral isotreti-
noin,	by	improving	the	epidermal	barrier	that	is	essential	to	prevent	
and	 reduce	 inflammation.	 Sunscreens	 and	 nicotinamide	 prevent	
postinflammatory	 hyperpigmentation.	 Cleansing	 agents	 suitable	
for	 oily	 skin	 or	 sensitive	 skin,	with	 ingredients	 that	 control	 seba-
ceous	secretion,	should	be	preferred.	Camouflage	with	non-come-
dogenic	makeup	is	useful	for	improving	women’s	self-esteem.4
Proper	and	honest	use	of	these	products	benefit	drug	treat-
ment,	 reduce	adverse	events,	decrease	 the	need	for	 topical	antibi-
otics and improve adherence/compliance to the therapeutic plan.4
Treatment of acne scars is a different chapter and will be 
treated separately. q
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